Learn the hidden signs of sleep apnea, its impact on health, and how effective treatment can restore your energy and improve ...

Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced that it has been honored with the Research and ...

ORLANDO -- Tirzepatide (Zepbound) improved symptoms of moderate-to-severe obstructive sleep apnea (OSA) in people with obesity, regardless of positive airway pressure (PAP) use, the phase III SURMOUNT ...

A nightly oral pill for obstructive sleep apnea is close to regulatory approval in the US. This medicine-based option could ...

Often brushed off as loud snoring, obstructive sleep apnea is a serious disorder that repeatedly cuts oxygen during sleep, strains the heart and brain, and raises the risk of hypertension, stroke and ...

(Reuters) -The U.S. Food and Drug Administration on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug greenlighted to directly treat ...

Incannex Healthcare Limited Sponsored ADR ( (IXHL) ) has provided an announcement.

The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity. Zepbound is a dual ...

Please provide your email address to receive an email when new articles are posted on . Individuals with moderate to severe obstructive sleep apnea had increased odds of having neovascular AMD.

Sleep apnea affects as many as 80 million in the U.S. Now Apnimed, the $400 million company behind the first ever pill to ...

Medical News Today looks at three key studies and their key findings that highlight and further confirm the connection ...